25 November 2017
News and Views
Links and Services
February's issue of the Alimentary Pharmacology & Therapeutics identifies predictors of dose escalation of adalimumab in Crohn’s disease patients.
Adalimumab is effective for the induction and maintenance of remission in Crohn’s disease-patient
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors